Acupuncture and Acupressure in Treating Patients With Moderate or Severe Pain Related to Stage III or Stage IV Pancreatic Cancer

NCT00040833 | Completed Phase 2

• 3 other identifiers: 02-008CDR0000069411NCI-G02-2082
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Acupuncture and acupressure may help relieve moderate or severe pain associated with stage III or stage IV pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of acupuncture and accupressure in treating patients who have moderate or severe pain associated with stage III or stage IV pancreatic cancer.

Conditions

Pain; Pancreatic Cancer

Keywords

stage III pancreatic cancer; recurrent pancreatic cancer; pain; stage IV pancreatic cancer

Interventions

complementary or alternative medicine procedure PROCEDURE

pain therapy PROCEDURE

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Diagnosis of stage III or IV primary pancreatic cancer * At least 4 days since prior change in type of pain medication * No change in dose of long-acting analgesics * Actual dose of as needed (PRN) pain medication may vary * One of the following pain scores: * Pain score of at least 4 on a scale of 0 to 10 * A score of at least 54 out of 88 on the combined relevant Profile of Mood States (POMS) subscales (Vigor, Fatigue, and Confusion) with no evidence that sedation results from cause other than opiate medication and patient reported using PRN opiates on at least 4 of the past 7 days (patients who are eligible for this study on the basis of POMS scores must be taking PRN medication) PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * Not specified Life expectancy: * At least 4 weeks Hematopoietic: * Absolute neutrophil count at least 500/mm\^3 * Platelet count at least 20,000/mm\^3 Hepatic: * INR no greater than 2.5 Renal: * Not specified Cardiovascular: * No heart valve dysfunction Other: * No uncontrolled infection PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 4 weeks since prior gemcitabine unless there is documented disease progression * Concurrent chemotherapy (except gemcitabine) allowed Endocrine therapy: * Not specified Radiotherapy: * At least 3 weeks since prior radiotherapy * No concurrent radiotherapy Surgery: * At least 1 week since prior epidural analgesia, celiac plexus block, or thoracoscopic or open splanchnicectomy * No concurrent epidural analgesia, celiac plexus block, or thoracoscopic or open splanchnicectomy Other: * See Disease Characteristics * At least 3 months since prior acupuncture * Concurrent experimental treatments allowed

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States

Location

MeSH Terms

Conditions

Pain; Pancreatic Neoplasms

Interventions

Analgesia

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Anesthesia and Analgesia

Study Officials

• Barrie R. Cassileth, PhD

  Memorial Sloan Kettering Cancer Center

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Purpose: SUPPORTIVE CARE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: July 8, 2002
• First Posted: January 27, 2003
• Study Start: February 1, 2002
• Primary Completion: June 1, 2003
• Study Completion: June 1, 2003
• Last Updated: June 5, 2013

Record last verified: 2013-06

Locations

US (1)